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Abstract
Thymidylate synthase (TS) is a key enzyme in the de novo synthesis of 2V-deoxythymidine-5V-monophosphate (dTMP) from 2V-
deoxyuridine-5V-monophosphate (dUMP), for which 5,10-methylene-tetrahydrofolate (CH2-THF) is the methyl donor. TS is an important
target for chemotherapy; it is inhibited by folate and nucleotide analogs, such as by 5-fluoro-dUMP (FdUMP), the active metabolite of 5-
fluorouracil (5FU). FdUMP forms a relatively stable ternary complex with TS and CH2THF, which is further stabilized by leucovorin (LV).
5FU treatment can induce TS expression, which might bypass dTMP depletion. An improved efficacy of 5FU might be achieved by
increasing and prolonging TS inhibition, a prevention of dissociation of the ternary complex, and prevention of TS induction. In a panel of 17
colon cancer cells, including several variants with acquired resistance to 5FU, sensitivity was related to TS levels, but exclusion of the
resistant variants abolished this relation. For antifolates, polyglutamylation was more important than the intrinsic TS level. Cells with low p53
levels were more sensitive to 5FU and the antifolate raltitrexed (RTX) than cells with high, mutated p53. Free TS protein down-regulates its
own translation, but its transcription is regulated by E2F, a cell cycle checkpoint regulator. Together, this results in low TS levels in stationary
phase cells. Although cells with a low TS might theoretically be more sensitive to 5FU, the low proliferation rate prevents induction of DNA
damage and 5FU toxicity. TS levels were not related to polymorphisms of the TS promoter. Treatment with 5FU or RTX rapidly induced TS
levels two- to five-fold. In animal models, 5FU treatment resulted in TS inhibition followed by a two- to three-fold TS induction. Both LV
and a high dose of 5FU not only enhanced TS inhibition, but also prevented TS induction and increased the antitumor effect. In patients, TS
levels as determined by enzyme activity assays, immunohistochemistry and mRNA expression, were related to a response to 5FU. 5FU
treatment initially decreased TS levels, but this was followed by an induction, as seen with an increased ratio of TS protein over TS-mRNA.
The clear retrospective relation between TS levels and response now forms the basis for a prospective study, in which TS levels are measured
before treatment in order to determine the treatment protocol. D 2002 Elsevier Science B.V. All rights reserved.
Keywords: Thymidylate synthase; p53; E2F; 5-fluorouracil; Antifolate
0925-4439/02/$ - see front matter D 2002 Elsevier Science B.V. All rights reserved.
PII: S0925 -4439 (02 )00082 -0
Abbreviations: 5FU, 5-fluorouracil; FUdR, 5-fluoro-2V-deoxyuridine; TS, thymidylate synthase; TSER, TS enhancer regions; FPGS, folylpolyglutamate
synthetase; dUMP, 2V-deoxyuridine-5V-monophosphate; FdUMP, 5-fluoro-dUMP; dTMP, 2V-deoxythymidine-5V-monophosphate; CH2-H4-folate, N5,N10-meth-
ylene-5,6,7,8-tetrahydrofolate; LV, leucovorin; RTX, raltitrexed, N-[5-(N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-yl-methyl)-amino)-2-thenyl)]-L-glutamic
acid (Tomudex, ZD1694); ALIMTA, multitargeted antifolate, N-(4-(2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-D]pyrimidin-5-yl)-ethyl)-benzoyl]-L-
glutamic acid (LY231514); GW1843U89, (S)-2-(5-(((1,2-dihydro-3-methyl-1-oxobenzo(f)quinazolin-9-yl)-methyl)-amino)-1-oxo-2-isoindolinyl)-glutaric
acid; AG337, nolatrexed, 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazoline (Thymitaq); SRB, sulforhodamine B; MTT, 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide; CDK, cyclin-dependent kinase; DPD, dihydropyrimidine dehydrogenase; wt-p53, wild type p53;
mt-p53, mutant p53
* Corresponding author. Tel.: +31-20-4442633; fax: +31-20-4443844.
E-mail address: gj.peters@vumc.nl (G.J. Peters).
www.bba-direct.com
Biochimica et Biophysica Acta 1587 (2002) 194–205
1. Introduction
Thymidylate synthase (TS) is a key enzyme in the de
novo synthesis of 2V-deoxythymidine-5V-monophosphate
(dTMP). TS catalyzes the methylation of 2V-deoxyuridine-
5V-monophosphate (dUMP) to dTMP for which 5,10-meth-
ylene-tetrahydrofolate (CH2-THF) is the methyl donor.
Detailed characteristics of the TS enzyme have been
described by others [1,2]. TS is an important target for
chemotherapy. It is inhibited by analogs of the folate
cofactor, such as raltitrexed (RTX) and ALIMTA, and the
nucleotide co-factor, such as 5-fluoro-dUMP (FdUMP),
which is the active metabolite of 5-fluorouracil (5FU).
FdUMP is a competitive inhibitor with a Ki in the low
nanomolar range. Inhibition of TS by FdUMP is considered
to be the main mechanism for the action of 5FU (Fig. 1). The
inhibition by FdUMP is mediated by the formation of a
covalent ternary complex between FdUMP, TS and CH2-
THF, while the retention of inhibition is also dependent on
the ratio between free dUMP and FdUMP levels [3,4]. A low
sensitivity to 5FU has been related to a rapid disappearance
of FdUMP. A high dUMP concentration or a limited FdUMP
binding to TS may reduce retention of TS inhibition.
Several mechanisms of resistance to 5FU have been
attributed to TS (Table 1) [5]. The stability of the ternary
complex is highly dependent on the availability of CH2-THF
or one of its polyglutamates [4]. LV can increase the avail-
ability of CH2-THF (Fig. 1). After transfer across the mem-
brane, mediated by the reduced folate carrier [6], LV will be
metabolized to CH2-THF [7], which will be polyglutamy-
lated leading to enhanced inhibition of TS [8]. A decreased
activity of folylpolyglutamate synthetase (FPGS) [9] and
altered binding of FdUMP to TS [10–12] have been asso-
ciated with acquired 5FU resistance. In the absence of CH2-
THF or one of its polyglutamates [5,12–14], FdUMP forms
an unstable binary complex, which results in poor inhibition.
Disturbed folate pools [14] (usually decreased) and a high
level of enzyme before treatment lead to intrinsic resistance
[5,11,12]. Gene amplification of TS andmutations in the gene
lead to acquired resistance [12,13,15]. This paper focuses on
the role of intrinsic TS levels and that of TS induction in 5FU
resistance and on their regulation in various systems.
2. Experimental procedures
2.1. Cell lines and tissues
The sources of the cell lines have been described previ-
ously [16,17]. Sensitivity to 5FU and antifolates was deter-
mined in 96-wells plates using either the sulforhodamine B
(SRB) or 3-[4,5-yl]-2,5-diphenyl tetrazolium bromide (MTT)
assays as described previously [16,18,19]. In some cell lines,
antifolates cause swelling of the cells leading to an increased
protein content, which interferes with the protein-based SRB
assay. In case this swelling was observed, we used the MTT
assay for antifolates. 5FU did not cause swelling. For all cell
lines, we added drugs 24 h after plating of the cells. Cells
were exposed for 72 h and linearity of growth was assured for
untreated cells during this 72-h period.
For enzyme assays, immunoblotting, RNA and DNA
extraction, all cell lines were cultured in 75-cm2 flasks and
harvested in the logarithmic growth phase by trypsinization,
then washed and counted. Thereafter, the cell pellets were
frozen in liquid nitrogen.
Tumors from animals were removed before and at differ-
ent time points after drug treatment and immediately frozen
Fig. 1. Metabolic conversions of 5FU. The enzymes involved in these
reactions are: (1) orotate phosphoribosyltransferase (OPRT); (2) uridine
phosphorylase (UP); (3) thymidine phosphorylase (TP); (4) uridine kinase
(UK); (5) thymidine kinase 1 (TK1); (6) thymidylate synthase (TS); (7)
dihydrofolate reductase; (8) dihydropyrimidine dehydrogenase (DPD); (9)
ribonucleotide reductase; (10) 5V-nucleotidases and phosphatases. Metabolic
pathways are depicted as solid lines. The inhibition of TS by FdUMP is
depicted as a broken line with a minus sign.
Table 1
Mechanisms of resistance to 5FU
(A) Decreased accumulation of activated metabolites
(a) Decreased activation
(b) Increased inactivation
(c) Increased inactivation of 5FU nucleotides
(B) Target-associated resistance
(a) Decreased RNA effect
(b) Altered effect on thymidylate synthase
. Aberrant enzyme kinetics
. Increased dUMP levels
. Decreased FdUMP accumulation
. Decreased stability of ternary complex
. Depletion of intracellular folates
. Decreased polyglutamylation of folates
. Recovery and enhanced enzyme synthesis
. Gene amplification
. Enzyme induction
(C) Pharmacokinetic resistance
(a) The drug does not reach the tumor
(b) Disease state affects drug distribution
(c) Increased elimination
Modified from Ref. [5].
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in liquid nitrogen. Tumors (primary tumors and liver meta-
stases) from patients were removed during surgery (after
administration of 5FU) and immediately frozen in liquid
nitrogen as described previously [20]. Frozen tissues were
pulverized [21] and the still frozen powder was further
processed in appropriate buffer either for enzyme assays
or RNA/DNA extraction.
2.2. TS enzyme assays
TS assays in cell lines were performed as described
previously [16]. We used two assays. One assay measured
the number of free FdUMP binding sites of TS by estimation
of the binding capacity of 3H-FdUMP. The other determined
the catalytic activity of TS by means of [3H]-H2O-release
during the TS catalyzed conversion of 3H-dUMP into dTMP.
Measurement of TS levels in tissues was slightly different
from that in cell lines, which has been previously described
[20,22,23]. In tissues from 5FU-treated patients and animals,
we measured TS levels in the extracts containing the non-
dissociated ternary complex, which enabled TS inhibition to
be expressed as the residual TS catalytic activity (TS-resid-
ual), and as the number of free binding sites for FdUMP (TS-
free).We also dissociated the ternary complex, which enabled
the measurement of total catalytic activity (TS-total) and all
available FdUMP binding sites (TS-tot). The ratios between
TS-residual/TS-total and TS-free/TS-tot ( 100%) was con-
sidered as the percentage inhibition.
2.3. TS immunoblotting
Protein expression was estimated using Western blotting
as described earlier [24,25]. Proteins were separated by size
through a 10% SDS-polyacrylamide gel and were electro-
phoretically transferred to a nitrocellulose membrane, on
which they were detected using horseradish peroxidase
(HRP)-conjugated secondary antibodies directed against
primary antibodies. The HRP reaction was visualized by
means of chemiluminescence and autoradiography.
2.4. TS immunohistochemistry
Sources of primary and secondary antibodies, staining
procedures and evaluation of staining have been described
previously [26,27]. A pathologist and two investigators
investigated all slides. Statistical evaluation was performed
using the nonparametric Kruskal–Wallis and Mann–Whit-
ney U ranking test. All values were based on two-tailed
statistical analysis. Survival was evaluated using Kaplan–
Meier curves. All statistical procedures were carried out
with SPSS 9.0 (SPSS, Chicago, IL, USA).
2.5. TS-mRNA expression
Total RNAwas isolated from pulverized tissues using the
RNAzole method and purity was checked by UV absorb-
ance and electrophoresis of 1 Ag RNA on a neutral 1.2%
agarose gel. cDNAwas synthesized from 5 Ag of total RNA
with 6 Ag of random primers using M-MLV reverse tran-
scriptase as described previously [28]. PCR amplifications
were carried out in a Perkin/Elmer/Cetus DNA thermal
cycler. A total of 25 cycles was used, in which each cycle
consisted of 1 min primer denaturation at 94 jC, 1 min of
primer annealing at 55 jC, and 1 min of primer extension at
72 jC. The cDNA samples were diluted depending on
transcript abundance, while three cDNA dilutions were used
for each primer in order to verify that measurements were
taken in the linear phase of the reaction. A detailed descrip-
tion of the procedure as well as the sequences of the primers
for the target gene TS and the reference genes h-actin and
18S are described previously [28].
2.6. TS enhancer region (TSER)
TSER was amplified [29,30] from genomic DNAwith the
sense primer (5V-GTGGCTCCTGCGTTTCCCCC-3Vand the
antisense primer: 5V-GCTCCGAGCCGGCCACAGG-
CATGGCGCGG-3V). PCR was carried out in 1 PCR
buffer (50 mM KCl, 10 mM Tris pH 9, 0.1% Triton
X-100), containing 1.25 mM magnesium chloride, 10%
DMSO, 0.2 mM dNTPs, 0.2 ng each primer, 50–100 ng
genomic DNA and 2.5 units of Taq in a 50 Al reaction.
Samples were overlaid with mineral oil and amplified in a
thermal cycler for 30 cycles. Each cycle was 1 min at 94 jC,
1 min at 60 jC and 2 min at 72 jC, and the final cycle was
maintained at 72 jC for 5 min. PCR products were separated
by electrophoresis on a 4% agarose gel and visualized with
ethidium bromide.
3. TS and p53 levels in relation to sensitivity to 5FU and
antifolates
3.1. Physiological regulation of TS levels
Expression of TS under physiological conditions is
related to the cell cycle, and has a high activity during the
S-phase [31], but decreases when the cells do not proliferate
[32]. Various transcription factors and cell cycle-dependent
kinases (CDK) control the increase in TS levels in the cell
cycle. Cell cycle progress through the G1/S checkpoint is
tightly regulated by cyclin/CDK complexes, which are
activated by phosphorylation. Phosphorylation of various
cyclins-CDKs can subsequently hyperphosphorylate the Rb
and E2F complex, which results in the release of E2F from
phosphorylated Rb. The free transcription factor E2F can
subsequently activate the transcription of several DNA
synthesis-dependent proteins such as TS.
TS levels are also controlled at the level of translation.
The translation of the TS-mRNA appears to be controlled by
its end product, the TS protein, in an autoregulatory manner.
This phenomenon possibly contributes to the large variation
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of TS levels not only in normal tissues, but also between
tumors and within tumors. TS protein cannot only regulate
its own translation but also that of other proteins, such as
p53 [33]. In addition, wild-type p53 (wt-p53) protein can
also inhibit TS promoter activity [34]. Thus, regulation of
TS expression is a very complicated process, which may
even be more disrupted (more induction) in cells with
mutated p53 (mt-p53) than with wt-p53 (low induction).
Although many nucleotide synthesizing enzymes are
increased in tumors compared to their normal counterparts
[35], the increase of TS levels in, e.g. colon tumors
compared to normal colon mucosa, varies from negligible
to many fold higher [36,37], and is even higher in meta-
stases compared to primary colon tumors [38,39]. This
increase was associated with an increase in p53 and cell
cycle genes. Consequently, in colon cancer cell lines and
tumors, a large variation in TS levels has been observed
[4,12,16–18,24,25,39–41].
3.2. Intrinsic and amplified TS levels in relation to sensitivity
to 5FU and antifolates
Since TS is the target for 5FU, it was hypothesized that
the large variation in TS levels would be related to 5FU
sensitivity. Indeed, in a small panel of cell lines consisting
of several 5FU-resistant cells and some nonselected cells,
Johnston et al. [17] found a relation between TS levels and
5FU sensitivity, but omission of the resistant lines weakened
this relation considerably. In a limited number of cell lines
with a different histological origin, Beck et al. [40] found a
weak correlation (r2 = 0.22, P= 0.042) between 5FU sensi-
tivity and TS levels, but in the subpanel of colon cancer
cells this relation was not present.
Recently, we reported TS levels in a panel of 13
unselected colon cancer cell lines, not including cells with
induced resistance. The TS catalytic activity varied from 62
to 777 pmol/h/106 cells, while the number of FdUMP
binding sites varied from 203 to 2758 fmol/mg protein
[16]. This panel has now been extended with several cell
lines with intrinsic TS levels in the same range and with cell
lines with induced resistance to 5FU described by Johnston
et al. [17]. In this panel, levels of the TS catalytic activity
were in a range up to 51,000 pmol/h/106 cells, and the
number of FdUMP binding sites in a range up to 6800 fmol/
mg protein (Fig. 2). In this extended panel including the
resistant cells, the number of FdUMP binding sites corre-
lated positively with the sensitivity to 5FU (r = 0.864;
P < 0.0001). However, when the resistant cell lines were
excluded (FdUMP binding sites varying from 203–2758
fmol/mg protein; 15 cell lines), no relation between TS
levels and 5FU sensitivity could be found. As shown in our
previous results, sensitivity to the antifolates RTX,
ALIMTA, AG337 and GW1843 was not related to the TS
levels [16]. However, the activity of FPGS was still pos-
itively correlated to sensitivity to both RTX and ALIMTA.
TS catalytic activity was significantly correlated to both
FdUMP binding (Fig. 2) and TS protein measured by
Western blotting as described previously [16,17]. TS levels
were also related to TS-mRNA expression. Recently, Grem
et al. [41] also observed a lack of correlation between 5FU
sensitivity and TS levels in the National Cancer Institute 60-
cell line panel, either evaluated as TS protein or TS-mRNA
expression. This lack of correlation might have several
reasons, such as the relatively short drug exposure time
(48 h), after which growth inhibition was determined. This
continuous presence of 5FU possibly leads to a complete
inhibition of TS independently of the endogenous TS levels
as was observed in cells with induced TS [32]. Thus, growth
inhibition might be dependent on additional parameters,
such as the extent of induction of DNA damage [42].
Alternatively, sensitivity to 5FU might also be dependent
on other parameters in addition to TS levels, such as toxicity
mediated by incorporation of 5FU into RNA. Recently,
Scherf et al. [43] investigated a large panel of mechanisti-
cally different drugs using cluster analysis after running
microarrays. 5FU clustered with drugs with an RNA-direc-
ted effect, rather than with other TS inhibitors.
It seems that very high amplified TS levels as found in
cells with acquired resistance to 5FU are only related to 5FU
sensitivity. In other cells, the mechanism of 5FU might not
be TS directed (e.g. RNA-mediated). Alternatively, the
continuous exposure to 5FU (varying from 48 to 96 h)
may produce sufficient FdUMP to inhibit TS intracellularly
to undetectable levels even in cells with a 10-fold difference
in TS levels. In an in situ TS assay, 5FU at IC50 levels
inhibited intracellular TS more than 50% within only 4 h in
cells with varying levels of TS [18]. With RTX, we
observed using in situ TS inhibition that a partial inhibition
after 4 h exposure increased to a complete inhibition after
24 h exposure [32]. Therefore, it seems that the usual in
Fig. 2. Relationship between FdUMP binding (fmol/mg protein) and
relative TS protein content as determined by Western blotting (Pearson
correlation 0.786; P= 0.002). TS protein was quantified using purified TS
as a standard. Updated from Ref. [16]. FdUMP binding was also correlated
with TS catalytic activity (expressed as pmol/h/106 cells) measured at
saturating substrate concentrations (r = 0.810, P= 0.0001) and at half-
maximal substrate concentration (r = 0.732, P= 0.003). TS catalytic activity
correlated with TS-mRNA expression (r = 0.733, P= 0.04).
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vitro cell culture conditions (continuous exposure) are not
representative for evaluation of a relation between TS levels
and 5FU sensitivity, and certainly not for an evaluation of
antifolate sensitivity [43]. The latter is due to the fact that
intracellular folate homeostasis will rescue cells from anti-
folate toxicity [44,45], especially when FPGS levels are
high, since this would enable trapping of normal folates as
polyglutamates in the cell.
3.3. Sensitivity to 5FU and RTX in relation to p53 ex-
pression
Besides the well-known and reasonably well-character-
ized resistance mechanisms of 5FU (Table 1), recently more
evidence for other potential mechanisms has been provided.
Ample evidence is now available that cytotoxic drug treat-
ment of cells will result in an induction of p53 in cells with
wt-p53 (reviewed in Ref. [42]). This will lead to an increase
of p21, which can inhibit cell cycle progress by inhibition of
CDK2, resulting in a cell cycle arrest and enabling the cells
to repair drug-induced DNA damage. Alternatively, p53
induction can also transactivate bax levels, which promotes
cell death. However, in cells with mt-p53, the expression of
bax also increased [24,25], and cells died, but without the
appearance of apoptotic features. In contrast, cells became
necrotic. The difference in p53 status indeed led to a
significantly different sensitivity for 5FU and RTX sensi-
tivity in wt-p53 and mt-p53 cells (Fig. 3). For 5FU, these
results are comparable to the increased 5FU sensitivity in
wt-p53 cells from the National Cancer Institute 60-cell line
panel compared to the cells with a mt-p53 expression
[41,46]. This might be related to higher susceptibility of
wt-p53 cells to enter apoptosis.
3.4. TS levels in relation to TS gene promoter polymorphisms
Evidence has been provided by Marsh et al. [29], that
polymorphism of TS gene promoter regions may be related
to TS-mRNA and protein expression. Tandem repeat
sequences near the initiation start site in the 5V-untranslated
region (5VUTR) of the human TS promoter act as a cis-
acting enhancer element in the TS gene and have been
shown to influence TS expression. These TSERs are poly-
morphic and contain either two or three 28-bp tandem
repeats. In vitro the triple tandem repeat (TSER*3)
increased the TS expression compared to the double tandem
repeat (TSER*2). Therefore, we also analyzed the tandem
repeats in our panel of cell lines (Table 2). Only two cell
lines (H630 and SNU-C1) showed a homogenous TSER*3,
and two other cell lines a heterogeneous double/triple
repeat. Interestingly, SNU-C1 and SNU-C4, which are cell
lines derived from the same patients, showed a different
TSER genotype. When the TS levels (activity, protein,
mRNA) in these lines (TSER*3 and TSER*2/3) were
compared with the other cell lines (all TSER*2), no sig-
nificant differences were found. In addition, the 5FU resist-
ant variants H630-R1 and H630-R10 also showed a
homogenous TSER*3, although their TS levels were mark-
edly increased compared to H630 cells. Apparently, in this
cell line panel, the tandem repeats do not influence TS
levels, or the number of cell lines was too small to draw
such conclusions.
Also in patients, the occurrence of tandem repeats has
been investigated. In DNA from 121 patients with colorectal
cancer, 29% of the patients were homogenous for TSER*3,
16% were homogenous for TSER*2 and 55% were hetero-
geneous [29]. In 44/45 paired samples, the TSER was
Fig. 3. Relation between p53 expression and sensitivity to 5FU and RTX.
Sensitivity was determined by means of a 72-h exposure to the drugs;
values are meansF S.E. of IC50 values (nM for RTX, AM for 5FU and
5FU-LV; LV was added at 10 AM). IC50 values for RTX and LV-5FU were
significantly lower (1) in cells with a wt-p53 (4 cell lines with a low p53;
P= 0.042 and 0.019, respectively) than in cells with a mt-p53 phenotype
(10 cell lines with high p53). For 5FU, this difference tended to be
significant ( P= 0.060). From Refs. [16,24].
Table 2
Expression of TSER and p53 in colon cancer cells
Cell line p53 TSER
SW620 mut 7.29 2/2
SNU-C4 wild 0.27 2/2
SW1116 mut 8.31 2/2
WiDr mut 7.86 2/2
WiDr/F mut 5.06 2/2
Colo320 mut 6.99 2/2
SNU-C1 wild 0.37 3/3
Lovo wild 0.09 2/2
LS174T wild 0.11 2/3
SW948 mut 0.08 2/2
HT29 mut 6.07 2/2
SW1398 mut 7.24 2/2
Colo205 mut 7.31 2/2
Colo201 mut 5.3 2/3
H630 mut n.d. 3/3
Blots were scanned for p53; actin was used to control blots for loading of
protein. The p53 status was based on mutation analysis reported; p53
expression were normalized on a reference amount of p53 protein. TSER
2/2 means that the cells were homogenous for the double repeat, 2/3 that
they were heterogeneous for the double and triple repeat, and 3/3 that they
were homogenous for the triple repeat. n.d., not done.
G.J. Peters et al. / Biochimica et Biophysica Acta 1587 (2002) 194–205198
similar in colon tumors and normal mucosa. Patients homo-
genous for TSER*2 had a longer survival than those with a
homogenous TSER*3. Also, Villafranca et al. [47] observed
that patients with homogenous TSER*2 and heterogeneous
TSER*2/3 tended to have a longer survival than patients
with a homogenous TSER*3 (81% vs. 41%, P= 0.17).
Iacopetta et al. [48] observed that from 221 patients with
Dukes’ C colon cancer, 26% were homogenous for TSER*3
and did not benefit from 5FU-based chemotherapy. How-
ever, those patients with a heterogeneous TSER*2/3 or
homogenous TSER*2 genotype showed significant gain in
survival (P= 0.005) from treatment. The value of the
genomic polymorphisms in the TS gene promoter region
should be investigated prospectively.
4. TS induction in cell lines
The regulation of TS levels in the cell cycle can be
disrupted by various TS inhibitors [49]. When FdUMP is
bound to TS in the ternary complex, the protein can no
longer autoregulate its own synthesis, leading to a dere-
pression and increase in TS protein. Thus, inhibition of TS
in vitro either by the formation of the ternary complex
between FdUMP, the enzyme and 5,10-CH2-THF [50,51],
or by specific TS inhibitors such as RTX [49], disrupt the
regulation of enzyme synthesis. This is shown as an
increase in TS protein expression, which is not accompa-
nied by an increase in TS-mRNA. The increase in TS
protein, however, may also be due to stabilization of the
protein due to decreased degradation of the ternary complex
[52]. The 5FU induced increase could be prevented by
interferon-g [53]. Increase in TS levels in cell lines after
exposure to 5FU or antifolate TS inhibitors seems to be a
universal finding, but it is not clear from the in vitro studies
whether this increase is related to sensitivity to 5FU or
antifolate TS inhibitors. The increase is usually between
two- and five-fold, but is concentration and time-dependent
[24,25,54]. Exposure to 5FU leads to an initial decrease in
free TS and an increase in the ternary complex (Fig. 4);
however, the total amount of TS protein exceeded that of
untreated cells [24,25,55]. In cells treated with RTX and
other antifolate TS inhibitors, free TS protein accumulated
in time [24,25,32,54]. In a panel of six colon cancer cell
lines, the extent of TS protein induction was not related to
sensitivity to 5FU or RTX [24]. Actually, in WiDr cells,
induction of TS protein by RTX was not sufficient to
prevent complete inhibition of TS in the in situ TS inhib-
ition assay [32]. Apparently, the continuous presence of the
inhibitor will lead to TS protein induction, but will also be
sufficient to allow complete inhibition of TS catalytic
activity. As mentioned above, this possibly also explains
the lack of correlation between TS protein levels and 5FU
and antifolate sensitivity.
5. TS levels and induction in solid experimental tumors
Evidence for a lack of relation (or at most a poor
relation) between TS levels and in vitro sensitivity patterns
for 5FU and antifolates is accumulating. However, this
does not mean that such a relationship would not exist in
vivo. Spears et al. [56] have already observed that exper-
imental colon tumors with a high TS activity were less
sensitive to 5FU. Although the reported panels are not as
large as for the in vitro studies, all together there seems to
be a reasonably good relationship between TS levels and
5FU sensitivity, despite the fact that in vivo pharmacoki-
netics determine 5FU concentrations. Actually, the similar-
ity of 5FU plasma pharmacokinetics between humans and
mice might be in favor for extrapolation of murine data to
humans [21]. Also, in our panel of tumors, we found that
5FU-sensitive tumors had a lower TS activity than 5FU-
resistant tumors [22,23,57]. Treatment with a therapeutic
dose of 5FU resulted in a more pronounced inhibition in
the sensitive tumors compared to the resistant tumors. In
addition, 5FU treatment resulted in a two- to three-fold
induction of TS in the resistant tumors, which already had a
high activity [22,23,57]. This TS induction was already
found 7 days after treatment with 5FU at 100 mg/kg and
was more pronounced after three treatment cycles (Fig. 5).
However, in the sensitive tumors, this induction was not
observed, and TS levels were further reduced following the
second and third injection. In the resistant tumors, the
induction could also be prevented by repeated administra-
tion, but only by the use of a higher dose of 5FU (150 mg/
kg) (Fig. 6). The latter is only possible when toxicity of
Fig. 4. Effect of 24- and 48-h treatment with 50 AM 5FU on TS levels in the
colon cancer cell lines, HT29, SW948, WiDr/F (all mt-p53) and LoVo (wt-
p53) and the p53 null myeloid leukemia cell line HL60. Data were
expressed as the ratio of (ODmm2)treated/(ODmm2)control. Specific
protein levels in drug-treated cells were expressed relatively to the specific
protein levels in the untreated control cells (at similar total protein loads; set
at 1). Data are from one representative experiment as described previously
[24]. , 5 free TS (36-kDa band) after 24 and 48 h, respectively; , l
ternary complex (38-kDa band) after 24 and 48 h, respectively.
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5FU to mice is selectively protected by uridine (or a uridine
prodrug) administration [58]. Uridine administration enabled
a 1.5-fold increase in the 5FU dose, which was also associ-
ated with an increased antitumor activity. Also, treatment
with 5-fluorodeoxyuridine (FUdR) resulted in a two-fold
induction of TS; however, for FUdR the onset of TS induction
was later (10 days) than for 5FU (7 days). FUdR, when given
as a bolus, was a more effective treatment than 5FU and is
thought to be entirely TS directed [57].
The most relevant clinically important finding was the
observation that the enhanced antitumor activity of the 5FU/
LV combination compared to 5FU alone, was associated
with the prevention of TS induction by LV (Fig. 5). The
combination of 5FU with LV and uridine provided a double
modulation: LV increased the antitumor effect of 5FU, while
uridine enabled to use a higher 5FU dose by protection of
gastrointestinal and myeloid toxicity. Uridine selectively
protects normal tissues since the toxicity is mediated by
incorporation into RNA [59,60], which is protected by
uridine. Uridine also protected 5FU-induced apoptosis in
the gut [61]. The double modulation resulted in the best
therapeutic efficacy compared to 5FU alone, since both LV
and an increased 5FU dose apparently provide an enhanced
and prolonged TS inhibition in tumors.
TS induction was not only observed in tumors, but also
in normal tissues. Local administration either by hepatic
artery infusion or isolated liver perfusion of 5FU are more
effective treatments than systemic administration, but may
result in local hepatotoxicty. Local administration of 5FU
not only exposes the liver metastases but also the normal
liver tissue to the high concentrations of 5FU. Local
administration of 5FU resulted in a pronounced inhibition
of TS in liver metastases ( > 70%) [62]. In contrast, local 5FU
administration resulted in a six- to seven-fold TS induction
in normal liver. Since no liver toxicity was seen with local
5FU administration, the induction of TS apparently provides
an additional protection of the normal tissues. Interestingly,
TS was also induced in normal gastrointestinal mucosa,
adding to a selective effect. Similarly, Welsh et al. [54]
observed a larger induction of TS in normal tissues compared
to tumor tissues, although this was after treatment with an
analog of RTX, ZD9331.
6. TS inhibition and induction in human disease
6.1. TS levels and inhibition in relation to response and
survival
Although one of the most widely used drugs, 5FU is only
moderately active in patients. Since modulation of 5FU with
LV enhanced in vitro cytotoxicity of 5FU and the in vivo
antitumor effect of 5FU (reviewed in Refs. [63,64]), the
combination was entered into the clinic and proved to give a
better therapeutic efficacy than 5FU alone [65], both in
terms of survival and response. In order to determine
whether tumoral TS levels and 5FU-induced inhibition
would be related to the response to 5FU, we gave patients
a 500 mg/m2 i.v. dose before surgery and removed the
tumors between 1 and 72 h after drug administration. Most
patients were subsequently entered in a clinical study in
which they were treated with a hepatic artery infusion of
5FU at a dose of 1000 mg/m2/day for 6 days. The study
aimed to determine what extent of TS inhibition in primary
human colon tumors and in liver metastases would be
Fig. 6. Effect of uridine (UR) and LV on 5FU-induced TS inhibition and
induction in Colon 26 tumors. Mice were treated weekly (days 0, 7, 14)
with 5FU alone at 100 mg/kg and in combination with uridine (3500 mg/kg,
2 and 18 h after each 5FU dose) at 150 mg/kg. LV was given as described in
the legend to Fig. 5. This 5FU dose was well tolerated because normal
tissue toxicity could be protected by providing uridine as a salvage
treatment. Values are meansF S.D. After 17 days, TS-total and TS-residual
were significantly higher after 5FU treatment compared to 5FU-UR and
5FU-UR-LV ( P< 0.02); after 3 days, TS-total, and after 17 days, TS-
residual were significantly higher after 5FU-UR compared to 5FU-UR-LV
( P < 0.05). From Ref. [58].
Fig. 5. Effect of 5FU treatment on TS levels (TS inhibition and induction) in
experimental tumors. Mice bearing Colon 26 (5FU resistant) or Colon 38
(5FU sensitive with complete remissions) were treated weekly (days 0, 7,
14) at the therapeutic dose of 5FU (100 mg/kg). LV was given as a double
dose of each 50 mg/kg, the first dose at 1 h before 5FU and one dose together
with 5FU [22]. TS catalytic activity in untreated tumors was 2.32F 0.72 and
0.80F 0.23 nmol/h/mg protein, respectively (meansF S.D.), and was set at
100%. Values are means; S.D. were less than 15%.
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sufficient to result in a response to 5FU. TS inhibition in
tumors is retained for at least 48–72 h after a bolus injection
of 500 mg/m2 5FU [20,66]. In those patients in whom the
TS activity in tumors remained low after 45 h, we observed
a significantly higher response compared to patients, in
which the activity was high. In 19 patients responding to
5FU hepatic artery infusion, TS levels in the tumor were
significantly lower than in the tumors from 21 non-respond-
ing patients (Fig. 7). In breast cancer patients, the number of
FdUMP binding sites increased and the effect of CH2-THF
decreased during development of resistance [67].
TS levels were also evaluated using immunohistochem-
istry, which essentially resulted in a similar pattern [26,27];
untreated patients had a relatively high TS expression in the
tumor, while 5FU administration decreased this level. After
45 h, most patients displayed a normal level of TS
expression. In addition, patients with a low TS expression
had a longer survival than patients with a high TS staining
(Fig. 8).
This study also evaluated the effect of LV on TS levels.
The TS assays not only enabled us to evaluate TS inhibition,
but by dissociation of the ternary complex also to evaluate
total TS levels. 5FU administration increased total TS levels
two-fold at 24 h (Table 3); LV not only increased TS
inhibition, but also reduced the TS induction. These clinical
data support the biochemical basis for LV modulation and
also demonstrate the validity of the translation of preclinical
data to the clinic.
6.2. Regulation of TS induction
Although immunohistochemistry gives a good insight in
the morphological distribution of TS, its discriminative
potential is rather poor, while the cytosolic staining of TS
is more difficult to quantify than an enzyme assay and
mRNA expression. Since TS-mRNA expression in colon
tumors is relatively low, Northern blots could not be used
and TS expression was quantified using RT-PCR with h-
actin and 18S as the reference genes. TS-mRNA expression
varied 17.7-fold relative to h-actin-mRNA and 41.7-fold
relative to 18S-rRNA (Fig. 9). TS-mRNA was correlated
with TS catalytic activity in these samples; both when
expressed as TS/h-actin (P= 0.8243, P= < 0.0001) and
TS/18S (r= 0.6226, P= 0.0034); also for FdUMP binding
capacity, a good correlation was found with TS-mRNA
Fig. 7. Relation between TS levels and response to 5FU treatment. Tumors
were removed from the patients at the indicated time points and im-
mediately stored in liquid nitrogen. TS-total levels (measured at 1 AM
dUMP) are given. The difference in TS levels between both groups is
significant at the level P< 0.01. Modified from Refs. [20,66].
Fig. 8. Relation between TS expression as determined by immunohisto-
chemistry and survival after 5FU treatment via hepatic artery infusion given
with a Porth-a-Cath (PAC). The Kaplan–Meier curves show the probability
of survival of 18 patients with liver metastases. Patients with a low
expression had a significantly better survival than those with a high
expression ( P= 0.025, log-rank test). From Ref. [27].
Table 3
TS levels in patients after 5FU administration
TS assay Drug/time
5FU
(2 h)
5FU
(23 h)
5FU
(45 h)
5FU/LV
(45 h)
TS catalytic activity (pmol/h/mg protein)
TS-total 21 53* 37 31
TS-residual 11 32* 30 13
FdUMP binding (fmol/mg protein)
TS-tot 58 128** 72 92
TS-free 0 22** 23 22
TS-mRNA expression
TS/h-actin ( 10 3) 4.2F 1.1 8.0F 1.5* 3.2F 1.0 n.a.
TS/18S ( 10 6) 1.5F 3.1 15.2F 5.0** 5.7F 1.5 n.a.
Values for TS catalytic activity and FdUMP binding are medians of 11–15
patients. TS-total is the total catalytic activity, and TS-tot the total number
of FdUMP binding sites, as measured after dissociation of the ternary
complex. TS inhibition is given as TS-residual, which is the catalytic
activity of TS, and TS-free, which is the number of free FdUMP binding
sites, as measured before the dissociation of the ternary complex was
performed [20]. The TS-mRNA expression (meansF SD) is a relative TS-
mRNA expression calculated as the ratio between TS-mRNA expression
and that of either h-actin or 18S [28]. Significantly different from the 2-h
values at the level: *, P < 0.05 or **, P< 0.02 using either Mann–Whitney
test (TS activity) or a Student’s t-test (TS-mRNA). Time points indicate
medians of the sample times. There was no significant difference in the h-
actin/18S expression ratio between the various time points.
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expression. Following 5FU treatment, the TS/h-actin ratio
significantly (P= 0.0493) increased two-fold from the 2 h
samples to the 23 h samples followed by a significant
(P= 0.0212) decrease from the 23 to 45 h samples (Table
3). Induction of TS was also found when comparing enzyme
activities at these time points.
In order to determine whether the amount of TS enzyme
per expression unit of TS-mRNA changed, we calculated
the ratio of enzyme levels relative to TS/h-actin. Interest-
ingly, the ratio catalytic activity compared to either TS/
hactin or TS/18S gradually increased (Fig. 10). However,
the ratio FdUMP binding compared to TS/h-actin or TS/18S
was induced at 23 h compared to 4 h, but decreased again at
45 h. For TS/18S, these data were significant. These data
indicate a greater induction of TS protein (as seen for the
FdUMP binding) relative to TS-mRNA. This is in line with
a TS autoregulation as proposed by Chu et al. [33,53].
According to this model, TS protein binds to TS-mRNA
inhibiting its own translation, TS bound by FdUMP will not
be not able to inhibit its translation, and the translation is
derepressed, leading to more enzyme synthesis. Since in 2-h
samples, the major part of TS is bound by FdUMP, the
autoregulation is disrupted and TS protein is synthesized
more compared to TS-mRNA. The TS protein then reaches
a plateau at 23 h when evaluated as the ratio TS protein/TS-
mRNA (measured as FdUMP binding capacity), but when
expressed as TS catalytic activity/TS-mRNA the ratio
increased. This indicates that more functional protein is
present after 45 h.
Altogether, the pattern of changes in TS-mRNA and TS
protein is quite complicated, and possibly due to a dual or
even triple effect in these tumors. Initially, TS bound by
FdUMP derepresses the autoregulation of TS-mRNA trans-
lation, leading to more synthesis of TS protein. Subse-
quently, the amount of E2F [26] increases, which induces
transcription leading to more TS-mRNA, encoding for even
more TS protein. Next to these effects, formation of the
ternary complex also leads to a stabilization of TS, with as
an ultimate effect an increase in total TS protein. Fortu-
nately, although TS protein is induced, FdUMP at suffi-
ciently high concentrations can still almost completely
inhibit TS. This was associated with a better response to
5FU therapy when the residual TS and free TS were below
certain thresholds [20].
7. Conclusions and perspectives
The expression of TS is controlled at several levels,
which may all affect the final enzyme catalytic activity in
the cell and the ability of drugs to inhibit the functional
activity of the enzyme. Since TS is the target for 5FU and
several folate-based TS inhibitors, it was expected that TS
expression would be related to the sensitivity to 5FU and
the antifolates. Acquired resistance to 5FU or antifolates
has indeed been associated with an increased TS expres-
sion (both at the mRNA and protein level) [5,11,15]. When
such cell lines are included in panels to evaluate a potential
Fig. 10. Effect of 5FU treatment on TS enzyme levels in relation to TS-mRNA expression. The ratio TS catalytic activity divided by the relative TS-mRNA
expression was calculated for each patient. Values are meansF S.D. The increase was significant ( P < 0.05) at 45 h for the TS/h-actin data and at 23 and 45 h
for the TS/18S data. Interestingly, for the ratio FdUMP binding/TS-mRNA, a peak (3-fold for TS/h-actin P= 0.0136; and 4.5-fold for TS/18S, P= 0.0115) was
observed at 23 h, while after 45 h, the ratio was back to that observed at 2 h.
Fig. 9. Relation between TS-mRNA expression (normalized to h-actin) and
TS catalytic activity (pmol/h/mg protein measured at 10 AM dUMP) in
colon tumors. The linear regression coefficient was 0.8243 with a
P < 0.001.
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relationship between TS levels and 5FU sensitivity, a sig-
nificant correlation has been found repeatedly [5,16,17].
When including resistant cell lines in our cell line panel,
5FU sensitivity was related to TS levels. Although we
previously reported a poor relation between TS levels and
5FU sensitivity [16], this relation did not exist when we
extended the cell line panel with more unselected cells.
Statistically, this unexpected finding might be explained by
inclusion of more data, which will correct for an intrinsi-
cally poor relationship. Mechanistically, the lack of corre-
lation may be explained by the fact that the cell lines are
exposed continuously to 5FU. This leads to a continuing
synthesis of FdUMP, which enables an almost complete
inhibition of TS. This has been seen in the in situ TS
inhibition assay with intact cells, in which TS activity was
still inhibited although TS protein was induced [32]. In
addition, a more pronounced effect may be found in
rapidly proliferating cells that tend to have a higher TS
activity [41]. The continuous exposure does not reflect
most commonly used schedules to treat either animals or
patients [5,21,65]. Currently, most treatment protocols
consist of bolus injections or short infusion up to 24 or
48 h, which will result in high drug levels for a relatively
short period followed by a rapid plasma clearance. Al-
though the drug is retained longer in tissues [21], contin-
uous exposure in vitro in cell lines does not reflect the in
vivo conditions in animals and patients. In cell lines, the
effect is quantified at the end of the exposure, while in
animals and patients, the response is evaluated after a
period of at least several weeks. Therefore, extrapolation
of experiments with cell lines should be done carefully,
taking into account these variations. In contrast, cell lines
can very well be used to study single parameters, such as
the potential mechanism of TS induction and the mecha-
nisms by which 5FU and antifolates can cause cell death.
In cell lines, it has also been shown that phosphorylation of
the protein [68,69] may affect TS activity, which might
explain some of the discrepancies between TS catalytic
activity and FdUMP binding. In addition, the presence of
antisense TS-mRNA [70] may affect expression of the
normal TS-mRNA.
Protein expression (either with immunohistochemistry or
Western blots) and TS-mRNA expression may reflect the
catalytic activity of TS in the cell. However, when cells are
treated, TS protein can be induced without a corresponding
increase in TS-mRNA levels. Several studies now report a
consistent relationship between intrinsic TS levels and
response and survival to 5FU-based chemotherapy
(reviewed in Ref. [71]). This relationship was found for
various types of cancer, when TS levels were evaluated
either by classical TS activity assays (e.g. Refs. [20,67]), TS
immunohistochemistry (e.g. Refs. [27,72]) or TS-mRNA
expression [73,74]. However, when the role of TS expres-
sion in adjuvant treatment of primary disease is evaluated,
the role of TS expression is less clear. For example,
Johnston et al. [72] reported that patients with a high TS
expression had a longer survival when treated with adjuvant
chemotherapy than patients with a low TS expression.
Apparently in primary disease other factors, such as pro-
liferation markers and repair enzymes may play another
important role [73,75]. Before using TS expression to select
patients for a specific type of adjuvant therapy, these factors
should be characterized in large patient populations. How-
ever, in advanced disease, the correlation between TS levels
and effect of 5FU is consistent throughout a variety of
studies [71]. Therefore, the type of treatment of advanced
colorectal cancer can be based on the TS expression in a
prospective manner. Patients with low TS enzyme levels
(TS activity, immunohistochemistry or mRNA) are expected
to respond better to a 5FU-based therapy than patients with
a high TS expression. When TS expression was combined
with that of dihydropyrimidine dehydrogenase (DPD), none
of the patients with high TS and DPD expression responded
to 5FU-based therapy [76]. These patients should be
selected for a non-5FU-based therapy such as with the
topoisomerase I inhibitor irinotecan or the platinum analog
oxaliplatin.
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